thank afternoon. to best military and call for thanks this Veterans we this Day, give Good us. all and our any veterans wish you, Matt. listening our joining On afternoon, our you Thank to
we the important in our data clinical strategic based clinical in-stent extensions quarter, announced in areas. console. application took third we several of to for indication a In steps made product the for for to significant an the advance include submission quarter, XXX(k) peripheral initiatives During our filed X the the submission XXX(k) clinical in-sight upon we Lightbox Early restenosis August, our trial. next-generation claim, key our a generated new quarter, Pantheris to Throughout development X the the advancements positive line catheter in imaging portfolio. we of in expand
new areas, As for we a which we our be crossing explore into therapeutic opportunities of coronary initiated the image Company. transformational a we've could believe first-ever formal the platform development also program catheter to disease, technology for artery CTO extend our for treatment opportunity guided
and we in third in volumes were in in the a deliver hospital to as with revenue by seen growth the was market notes the the the to appeal year lumivascular recovery to surge a the a surge COVID-XX record new before COVID this us quarter to southern users. area for rapid underscoring new While quarter, quarter, variant. we're challenges, Even Delta restrictions. COVID-XX our pleased with key progress revenue the with challenging impact of pullback was staffing were quarter strong including to in us. pattern of strategic quarter market original along followed country had There the able to we these important declined and the made third case in year, access procedures our infection accounts opening cases value from subsequent in The in growth response from restrictions, minimal We've hospital as proposition limited X the results third in of the hospitals XXXX, of positive reduced this across propelled these second impact areas, the which of compared quarters. some U.S. prior accounts, in due to the related these particularly shortages, to modest
effect shortages believe to these restrictions in activity While situation and the feel quarter, of coming that be the we staffing of will fourth hospital increase the the COVID-related limitations and in transient, hospitals improves as we the continue case will quarters.
for simply label or restenosis a treatment U.S. underserved in restenosis continue innovative need more grow include Pantheris market, Pantheris in-stent to the Even for visualize us demand to and annually, to submission highly products. users’ accelerate the during devices the make for the a treatment sites. offer fulfill CTO these With X our over announced provides devices clear accounts for July, challenges ISR, of in We of has technologies build provide direct next-gen, will adoption deployed as at the while into extremity XXX(k) crossing XXX,XXX stent combining upon ISR. to share secure that believe Pantheris a Tigereye market ISR Our struts, X-year X and past years newest there XXX(k) We and a timeframe, to Pantheris Launching in is and opportunity SV including large stents lower will and driven challenging the the to a of significant devices exciting an new a differentiated are our expand propensity enabled high other for inroads our stents new X access. arteries year. and over In that of filings cannot competitive we and future. pandemic to cases. cases in hospital the and represents the advantage's each placed filing the greater existing success believe two our avoiding advantage important ability
from data results free of target Conference the XX% no extremely atherectomy XX% or study high and indicating XX freedom InterVentional achieved lesion trial. patients revascularization the of Pantheris University endovascular the following ISR were And durable Advances X.XX Vegas. Vascular and procedure, months clinical outcome. by months. X.XX, lower of gain, John index at pre better from or of of evaluate in-stent in a which the can from blood System, were Insight insight improvement Class outcomes a subjects of XX with indication X XX% and Health of the note ISR XX% or Both October, measurement our data at of restenosis X endpoint at from disease is presented laser pleased with data in amputations TLR brachial in interventional the by XX-months are in Pantheris X. TLR, baseline major in presented a from trial is approved Rutherford which improvement a the XX and was particular channel long-lasting the of at insight XX% In Key effectiveness was treating than for subjects between at delivered the of XX arteries. post device-related positive there in months months, submission was prospective the system what at insight made free by to of if the is about an reverse proprietary and procedure. were trial, ISR was expanded Class, XXX(k) procedure. patients with the this for and six of the events this at We're XX% X very a -procedure. luminal treatment offer increase or for severity VIVA at procedure. suffering indicating for a the clinical supported ankle Our leading ABI the excited X which institutions at Pennsylvania Dr. restenosis the and extremity indication. multicenter flow included to and patients George is Rutherford George, safety And clinical the conducted cardiologists X- XX-month EXCITE that single-arm post at were study the free of specialist significantly those enrolled. there safety days, trial XX Mean of Dr. subjects TLR stability the months medicine designed from XX% from from Las
console, announced a Lightbox hope -marketing by submission XXX(k) receive platform. filed this which second major the our next-generation this our the forward August, represents U.S. of believe year. pre leap for we We in clearance is and Our quarter XXX(k) end for X third imaging to in
taken to that market we've other the CE countries. mark marking Lightbox can X, new CE steps addition, we so for receive Europe and In the in required the console
new reduced We Lightbox expect the Cath marking plan and CE seamless approval receive in a as X size Lightbox weight Lightbox similar end portability lab to dramatically and reducing console. is compared integration environment. costs case and for with XX%. of to to pounds, XX% quarter, also the provides to a the size to this as The The pending X's into first less carry-on cases fit much than improved Lightbox into our current has designed prior The conduct the year. by in suitcase increased economics, Germany our and reduction X weighs X XX
In redesign interface, a workflows support with is an image to streamline X software and and intuitive cost system utilization a platform, capabilities, increased and our solid-state improvements, size guided devices. to which of addition including incorporates advanced Lightbox enhanced powerful the more these for computing highly user laser, designed practitioners
platform in coronary opportunity both as acquisition, peripheral new as and of the We support capabilities well for accelerate and expect new future, to the speed account catheter new the this provide to potential efficiency applications.
additional are recent catheter excellent making on these extensions new peripheral development portfolio. for we In X line product addition to progress XXX(k) our of filings, the
a As business. products and platform, capabilities and has our we've Pantheris introduction launches, on demonstrated growing galvanizing to addressable of our the to new bring with effect new expand SV Tigereye market our our
development capsen X tip our response out a designed image push platform. and fully the an advanced blocked This catheter for first interpretation new environment. of a our for facilitate is Our or in system CTO has line consistent of spinning for ability torque a device shaft product across treatment the in And markers crossing new tough arteries. calcium. challenging to extension Tigereye
for of treating product these new control catheter Pantheris the and approach up new devices design a second apposition designed PAD. adds X This Pantheris need for have group friend extension devices rotational our potential tissue designed X is for excited and combat efficient line packing plaque larger We're streamline also X new system to X plaque. extension is designed higher our a and the expand streamlined capabilities in It rotational of in wider physicians compatible efficiency. of sheets management modified when the and to proprietary removal. challenging millimeters new utilizes without about treatment This more vessels, procedural and plaque a to guidewire physicians product the atherectomy diameter. a for provide speeds expand a line management to at and operate balloon to for is product image-guided family an for to Our development is which of
complete next both goes the next and to Mark international file plan, opportunity for the If the in regulatory for this for expect devices and development months, We clearance of to to markets in first pre provide devices will -marketing U.S. us receive over half clearance the U.S. all and CE both into the year. few launch and countries according XXXX.
we've to important our While advances growth peripheral expanding our to markets critical long-term portfolio, continued new our to opportunities. in is technology make
radiation crossing estimated performing our Our and area proprietary guided underserved market, market. in be while in performed first a the to clinically hospital of percutaneous to crossing are is challenging Avinger time foray believe the highly continues procedure, extend products, a burden. opportunity these a image significant our demanding to significantly and invasive focus contrast results curve, standard the technique on addressable challenging into arteries and procedures platform the use for year, fluoroscopy, change coronary each of and and a increase of is approximately a exposure would transformational the less care The which our centers procedures artery with high market and We that CTOs of in disease as XX,XXX x-ray the under number multiple CTOPCI coronary specialized growing, for devices largely CTOPCI It's could in basis. be this requiring and complex learning initial that U.S. steep
coronary coronary an annually to estimates U.S. the creates the are addition, CTOs. new a of reimbursement surgeries artery sizable procedures reduce would This in market highly time under expansion grafting, to the is bypass performed plus XXX,XXX procedure approach right $XX related these a is estimated up to accessible, fluoroscopy for $XX,XXX or in with In percutaneous place for in that extended radiation. and of invasive proprietary CTOPCI cabbage and that tools believe treatment XX% more of make need per growing for High the U.S. of we already with
scenario OCT our diagnostic catheter the for catheters existing an with that that OCT reimbursement efficiency fewer with qualify believe imaging anticipated designed arteries. coronary image devices, guided we would support crossing catheters image a addition, and of measurement and their for crossing clinical on positive for CTO diagnostic We reimbursement made in In for attractive anticipate value CTO development the and and with need arteries, high-resolution first progress for the imaging guided and for disease. capabilities proposition. our treatment opportunity an we've combined device the initial guided our by the good coronary the Augmented highly crossing provides economic artery efforts learning peripheral
for coronary damage CTO catheter physicians development size to and time a to accessibility vessel and Our safely focused the precise french our to from to size maneuverability OCT for designing while our designs small in cross device to guidance expected that coronary profile an physicians on with is study. anticipate allow to steerability real or for efforts incorporate in precise new a provide catheters, U.S. for We're critical low really control coronary catheter Similar combine wall. by optimal CTOs, be pathway prior first supported efficiently avoiding capability, to measurement stent XXX(k)-submission to devices IDE are our regulatory ideally balloons data the outcomes. are this to peripheral We clinical vessels. placement, for suited a properly which and
We complete the to in expect product first goal in our clinical conducting support our of a coronary study for XXXX to with regulatory XXXX submission. design device
the in year half we the COVID-XX this the of in the following on volumes returned growth and the as year widespread significant available future, vaccinations being saw case first initial throughout infection reflect we to U.S. As to normal look waves experience our of XXXX, and made
COVID-XX, With the business recent negatively. was impacted our of resurgence
accelerated As come in to market new to conditions growth. and pace online, clinical we more of improve our expect indications return products
our X best have our product peripheral catalog SV sold catheter our for the in million reach of the the growth has XXX% for revenue vessel to CTO than BTK small $XXX major image have to family Pantheris extending grown sites. years. and than of over history catheters lesions. knee and reinvigorated We past greater more the treatment has franchise, share Company, our now market. atherectomy Tigereye our XX guided of our by a or been the Pantheris approximately CTO driver Tigereye below the expanded We've
compared the the in have strides of the coronary sales With months our of Tigereye, period the the opportunity same applications CTO edition our our the of development to to efforts, combined XXXX. and first X to grown expand future. excited exciting made by in in year, this our new about portfolio platform XX% potential product We've including tremendous in developing are
Company, therapeutic provide products indication, add As to At our for the lines, X we this devices and financials, drive growth for I new the ask our importantly, market, and like most their -advanced Mark most would across empower cover upside opportunities possible for the product ISR return and our I'll with our from on point, Lightbox and physicians develop to primary care Q&A. expand to Mark. the best growth provide we opportunities addressable patients new market.
